research An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis
Tofacitinib may help treat severe hair loss, but more research is needed.
Search
for
Sort by
Research
240-270 / 414 results 
research Tofacitinib for the Treatment of Lichen Planopilaris: A Case Series
Oral tofacitinib can significantly improve recalcitrant lichen planopilaris.
research Review Article: Dermatological Complications of Immunosuppressive and Anti-TNF Therapy in Inflammatory Bowel Disease
Immunosuppressive and anti-TNF therapies in IBD patients can increase the risk of skin cancer and cause various skin issues.
research Efficacy of Topical Tofacitinib in Promoting Hair Growth in Non-Scarring Alopecia: Possible Mechanism via VEGF Induction
Topical tofacitinib may grow hair better than minoxidil by increasing VEGF and reducing inflammation.
research Harnessing the Power of Regenerative Therapy for Vitiligo and Alopecia Areata
Regenerative therapies show promise for treating vitiligo and alopecia areata.
research Ruxolitinib Rescues Multiorgan Clinical Autoimmunity in Patients With APS-1
Ruxolitinib significantly improves multiple autoimmune conditions in APS-1 patients.
research Topical SCD-153, A 4-Methyl Itaconate Prodrug, For The Treatment Of Alopecia Areata
SCD-153 shows promise as an effective topical treatment for alopecia areata.
research An Urticarial Drug Eruption Caused by Tofacitinib for Alopecia Universalis
A patient with alopecia had hair regrowth with tofacitinib but developed a skin reaction, choosing to continue the treatment despite the side effect.
research NF-κB in Biology and Targeted Therapy: New Insights and Translational Implications
NF-κB signaling is crucial in many diseases and can be targeted for new treatments.
research Molecular Correlation With Clinical Outcomes in an Open Label Clinical Trial of Oral Tofacitinib in Patients With Alopecia Areata
Tofacitinib helped most patients with alopecia areata regrow hair and changes in immune cells were linked to the treatment's effectiveness.
research STAT5 Activation in the Dermal Papilla Is Important for Hair Follicle Growth Phase Induction, Hair Follicle Regeneration, and Wound Healing
Activating STAT5 in the skin's dermal papilla is key for starting hair growth, regenerating hair follicles, and healing wounds.
research Drug Armamentarium for Alopecia Areata
No cure exists for alopecia areata, and treatments are personalized.
research Chemokine Receptor CCR5 as a Novel Target for the Treatment of Alopecia Areata
Blocking the CCR5 receptor may be a new way to treat hair loss from alopecia areata.
research Sterol Intermediates of Cholesterol Biosynthesis Inhibit Hair Growth and Trigger an Innate Immune Response in Cicatricial Alopecia
Cholesterol-related compounds can stop hair growth and cause inflammation in a type of scarring hair loss.
research Ruxolitinib Found to Cause Eyelash Growth: A Case Report
Ruxolitinib treatment may cause eyelash growth.
research Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development
Ritlecitinib shows promise as a versatile treatment for various autoimmune and inflammatory diseases.
research XMU-MP-1 Induces Growth Arrest in a Model Human Mini-Organ and Antagonizes Cell Cycle-Dependent Paclitaxel Cytotoxicity
XMU-MP-1 stops cell growth in a human mini-organ and reduces the effectiveness of the chemotherapy drug paclitaxel.
research Real-World Experience and Long-Term Evaluation of Tofacitinib in Refractory Alopecia Areata: A Prospective, Open-Label, Single-Center Study in Asian Arab Population
Tofacitinib is a promising treatment for severe alopecia areata, with many patients experiencing complete or partial hair regrowth.
research Systemic Tofacitinib Treatment in Pediatric Patients with Resistant Alopecia Areata
Tofacitinib is a safe treatment for hair loss in children, but long-term use may be needed for best results.
research Use of Ritlecitinib for the Treatment of Alopecia Areata
Ritlecitinib effectively treats alopecia areata in patients 12 and older with fewer side effects.
research Alopecia Areata: Current Understanding and Management
Alopecia areata is a chronic condition causing hair loss, with new treatments targeting the immune system showing promise.
research Baricitinib: A Review in Severe Alopecia Areata
Baricitinib helps regrow hair in severe alopecia areata but has side effects like infections and headaches.
research Hair Growth-Promoting Effects of Enz MoriL on Human Dermal Papilla Cells Through Modulation of the Wnt/β-Catenin and JAK-STAT Signaling Pathways
Enz_MoriL from mulberry leaves helps hair growth by affecting specific cell pathways.
research Effectiveness and Safety of Baricitinib in Patients With Moderate-to-Severe Refractory Alopecia Areata in Real World: An Open-Label, Single-Center Study
Baricitinib effectively and safely improves hair growth in patients with severe alopecia areata.
research Alopecia Areata: A Review of Diagnosis, Pathogenesis, and the Therapeutic Landscape
New treatments for alopecia areata show promise, but standardized guidelines are needed.
research Updates From 2021 Virtual Dermatology Nurses' Association Convention
The convention discussed various skin conditions, treatments, and the importance of continuous learning in dermatology nursing.
research The Role of Lymphocytes in the Development and Treatment of Alopecia Areata
Lymphocytes, especially CD8+ T cells, play a key role in causing alopecia areata, and targeting them may lead to new treatments.
research Frontal Fibrosing Alopecia: An Update on the Hypothesis of Pathogenesis and Treatment
The document concluded that more research is needed to find the best treatment for Frontal fibrosing alopecia.
research Steroid-Free Monotherapy with Tofacitinib in Severe Therapy-Resistant Alopecia: A Retrospective Analysis
Tofacitinib was effective for severe, treatment-resistant hair loss without side effects.
research Impact of Combined Baricitinib and FTI Treatment on Adipogenesis in Hutchinson-Gilford Progeria Syndrome and Other Lipodystrophic Laminopathies
Baricitinib and its combination with lonafarnib improve fat cell formation in certain genetic disorders.